At ESMO 2014, Dr Jennifer Temel is interviewed about the results of a phase III trial investigating the use of anamorelin in NSCLC patients with anorexia and cachexia. She discusses the next steps for anamorelin with a focus on regulatory approval and impact in clinical practice.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content